COVID-19 et psoriasis chez l’enfant. Données d’une cohorte internationale

Zitouni, J.; Fortina, Anna Belloni; Bursztejn, Anne‐Claire; Beauchet, Alain; Lesiak, Aleksandra; Мурашкин, Н. Н.; Maruani, Annabel; Lernia, Vito Di; Lasek, A.; Bretèque, M. Amy de la; Torres, Tiago; Епишев, Р. В.; Bourrat, E.; Bachelez, Hervé; Mahé, E.

doi:10.1016/j.fander.2021.09.439

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Psoriasis is a chronic inflammatory skin condition that may be triggered by stress, certain medications, and infections, including COVID-19 [3][4][5]. However, the association between vaccination and the worsening of psoriasis has been reported mainly after vaccines against influenza (H1N1), pneumococcal pneumonia, and yellow fever [6].…”

Section: Discussionmentioning

confidence: 99%

“…There are certainly possible cutaneous adverse reactions of COVID vaccination, including urticaria, morbilliform rash, pityriasis rosea, and the exacerbation of pre-existing dermatoses [1,2]. Psoriasis is a chronic cutaneous inflammatory condition that may be triggered by stress, certain drugs, infection, including COVID-19, and less commonly, vaccines [3][4][5][6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Psoriasis worsening related to COVID-19 vaccination: Report from a single-center

Boubnane¹,

Faras²,

Aboudourib³

2023

Our Dermatol Online

View full text Add to dashboard Cite

Background: Recently, reports have described cases of the onset or exacerbation of psoriasis related to COVID-19 vaccination. In this study, we sought to describe the clinical features and evolutionary aspects of psoriasis exacerbation after COVID-19 vaccination. Materials and Methods: This was a prospective and descriptive study conducted over a period of eighteen months at the Department of Dermatology and Venereology of the Mohammed VI University Hospital in Marrakech. We included all patients followed for psoriasis who received at least one dose of Sinopharm, AstraZeneca, or Pfizer COVID-19 vaccine. Results: A total of 148 patients were included in the study, among which 69 received a Sinopharm vaccine, 48 received an AstraZeneca vaccine, and 31 received a Pfizer vaccine. The mean age was 49 years. There were 82 males and 66 females, giving a sex ratio of 1.6. The comorbidities included hypertension in 27.7% of the cases, diabetes in 14.8%, dyslipidemia in 10.8%, and thyroiditis in 2%. Eight exacerbations of psoriasis after COVID-19 vaccination were noted. The mean duration of lesion development was 11.5 days. The vaccines involved were Sinopharm in 5 patients and AstraZeneca in 3 patients. The median PASI before vaccination was 7.8 and the median PASI after vaccination was 20.5. Three patients presented with severe erythematous lesions requiring hospitalization and the introduction of systemic therapy. Extension of the lesions to localized psoriasis was noted in five patients. Conclusion: COVID-19 vaccination may be a trigger for psoriasis, as suggested by multiple studies. However, these events should in no way contraindicate vaccination in patients with psoriasis. Key words: vaccination; COVID-19; psoriasis; exacerbation

show abstract